Eledon Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference

Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ: ELDN), a clinical-stage biopharmaceutical company, announced a corporate presentation at the Ladenburg Thalmann Healthcare Conference on July 13 at 2:00 pm EST. The company focuses on developing treatments targeting autoimmune diseases, organ transplant requirements, and ALS. Its lead compound, AT-1501, is an anti-CD40L antibody designed to enhance efficacy and safety by inhibiting CD40L, thus regulating immune responses. A replay of the presentation will be available for 30 days post-event on the company’s website.

IRVINE, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that management will present a corporate overview at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13^th at 2:00 pm EST.

To register in advance for the corporate presentation webcast, sign up here.

Replay Link:
A replay will be accessible for 30 days following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.

About Eledon Pharmaceuticals and AT-1501

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company’s lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may also play a therapeutic role for autoimmune diseases and in the transplant setting. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: @Eledon_Pharma and LinkedIn.

Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com

FAQ

What is Eledon Pharmaceuticals presenting at the Ladenburg Thalmann Healthcare Conference?

Eledon Pharmaceuticals will present a corporate overview highlighting its developments and strategies at the Ladenburg Thalmann Healthcare Conference on July 13 at 2:00 pm EST.

When is the Eledon Pharmaceuticals presentation scheduled?

The presentation by Eledon Pharmaceuticals is scheduled for July 13 at 2:00 pm EST.

What is AT-1501 and what is its significance?

AT-1501 is Eledon Pharmaceuticals' lead compound, an anti-CD40L antibody aimed at treating autoimmune diseases, organ transplant needs, and ALS, designed to offer better safety and efficacy.

How can I access the Eledon Pharmaceuticals presentation replay?

A replay of Eledon's presentation will be available for 30 days on their website's Events page following the live session.

What therapeutic areas is Eledon Pharmaceuticals focusing on with AT-1501?

Eledon Pharmaceuticals is focusing on autoimmune diseases, organ or cell-based transplants, and amyotrophic lateral sclerosis (ALS) with its lead compound AT-1501.